Table 1 Summary of baseline characteristics and response of patients treated with teclistamab.
From: Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
Patient | Baseline dFLC (mg/dl) | Baseline NT-proBNP (pg/ml) and NYHA Class | Mayo 2004 staging at teclistamab start | Baseline proteinuria (g/24 hours) | Organs Involved | Number of Prior Lines of Therapy | Best Hematologic Response | Organ Response | Vital Status |
|---|---|---|---|---|---|---|---|---|---|
#1 (60 y/o M) | 5.28 | 3307; NYHA II | II | 1.67 | Heart Kidney Peripheral Nerves | 7 | Heme-CR | Cardiac organ response achieved (Renal response not assessed) | Alive (in Heme-CR) |
#2 (79 y/o F) | 5.82 | 19,557; NYHA III | IIIb | 9.76 | Heart Kidney | 3 | Heme-CR | Cardiac and Renal organ response achieved | Alive (in Heme-CR) |
#3 (60 y/o F) | 20.5 | 17,035; NYHA I | IIIba | Not evaluable (patient on peritoneal dialysis) | Kidney | 5 | VGPR | Not evaluable | Alive (in VGPR) |
#4 (65 y/o F) | 13.55 | 614; NYHA I | II | 0.075 | Heart Autonomic Nervous System GI Tract | 6 | VGPR | Not evaluable | Alive (in VGPR) |
#5 (58 y/o F) | 476.7 | 8601; NYHA IV | IIIb | 0.075 | Heart Kidney GI Tract Musculoskeletal System | 7 | VGPR | No Response | Dead (in VGPR at the time of death) |
#6 (59 y/o F) | 21.34 | 214; NYHA I | I | 0.12 | Heart | 3 | VGPR | Not evaluable | Alive (in VGPR) |
#7 (71 y/o M) | 35.93 | 1487; NYHA II | IIIa | 0.46 | Heart Kidney GI Tract | 2 | VGPR | Cardiac Organ Response Achieved | Alive (in VGPR) |
